Research programme: anticancer therapies - Chong Kun DangAlternative Names: 3,5-dimethoxy-4-hydroxyethoxycinnamoyl fumagillol; 4-hydroxyethoxycinnamoyl fumagillol; CKD-731
Latest Information Update: 13 May 2010
At a glance
- Originator Chong Kun Dang
- Class Esters
- Mechanism of Action Angiogenesis inhibitors
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
On Fast track
Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.
Highest Development Phases
- No development reported Cancer